Core cerebrospinal fluid biomarker profile in cerebral amyloid angiopathy: A meta-analysis
Core cerebrospinal fluid biomarker profile in cerebral amyloid angiopathy: A meta-analysis
复制标题
DOI：
10.1212/wnl.0000000000005030
复制
发表时间：
2018-02-27
期刊：
影响因子：
9.9
通讯作者：
Viswanathan, Anand
中科院分区：
文献类型：
--
作者：
Charidimou, Andreas;Friedrich, Jan O.;Viswanathan, Anand
目的对4种CSF核心生物标志物进行荟萃分析（-淀粉样蛋白[A]42，A40，总tau蛋白[t-tau]和磷酸化tau蛋白[p-tau]），以评估其中哪些在散发性脑淀粉样血管病（CAA）中改变最多。在有症状的散发性CAA组群中与对照组和阿尔茨海默病（AD）患者相比，观察神经变性（A42，A40）、神经变性（t-tau）和缠结病理学（p-tau）。在基于平均（RoM）生物标志物浓度比值的随机效应荟萃分析中评估了生物标志物性能：（1）CAA患者与健康对照组和（2）CAA患者与AD患者。RoM >1表明CAA患者的生物标志物浓度高于对照人群和RoM
ObjectiveTo perform a meta-analysis of 4 core CSF biomarkers (-amyloid [A]42, A40, total tau [t-tau], and phosphorylated tau [p-tau]) to assess which of these are most altered in sporadic cerebral amyloid angiopathy (CAA).MethodsWe systematically searched PubMed for eligible studies reporting data on CSF biomarkers reflecting amyloid precursor protein metabolism (A42, A40), neurodegeneration (t-tau), and tangle pathology (p-tau) in symptomatic sporadic CAA cohorts vs controls and patients with Alzheimer disease (AD). Biomarker performance was assessed in random-effects meta-analysis based on ratio of mean (RoM) biomarker concentrations: (1) in patients with CAA vs healthy controls and (2) in patients with CAA vs patients with AD. RoM >1 indicates higher biomarker concentration in patients with CAA vs comparison population and RoM